Oncology News Recap: Novel T Cell for Hodgkin Lymphoma, and More

Each week on DocWire News, editors bring you the latest hematology and oncology news and research. In case you missed it, here are this week’s top headlines.

The highlights:

Pilot Study: Antigen-Targeted T Cell Therapy for HL Is Safe

Blood Cancer Awareness Month Spotlights Hematologic Cancers

Somatic Mechanism Evolution of MDS and AML in Short Telomere Disorders

Keep reading for the breakdown on these top stories!

Pilot Study: Antigen-Targeted T Cell Therapy for HL Is Safe

Results from a pilot study found that a novel T cell therapy combination for Hodgkin lymphoma was safe and showed promising results as an adjuvant therapy for patients with relapsed/refractory disease. The investigators evaluated treatment with a tumor-associated antigen (TAA)-specific T cell therapy either alone or with the checkpoint inhibitor nivolumab.  No dose-limiting toxicities occurred, and two of ten patients remained in continued remission after ≥2 years.

“The fact that this combination therapy is so safe was very encouraging for the treatment of patients with lymphomas,” said Catherine Bollard, MD, MB ChB, director of the Center for Cancer and Immunology Research at Children’s National Hospital, via a press release. “In addition, this data allows us to consider this combination immunotherapy for other patients, including those with solid tumors.”

Pilot Study: Antigen-Targeted T Cell Therapy for HL Is Safe

Blood Cancer Awareness Month Spotlights Hematologic Cancers

Did you know September is Blood Cancer Awareness Month? This month, take the time to learn more about these diseases, which impact more than 1.3 million Americans. Every three minutes someone in the U.S. is diagnosed with a blood cancer, which are the third leading cause of cancer-related death nationally.

Read on to learn more about the different types of blood cancer and how how cancer research and advocacy organizations are celebrating the month.

Blood Cancer Awareness Month Spotlights Hematologic Cancers

Somatic Mechanism Evolution of MDS and AML in Short Telomere Disorders

A study assessed the presence of somatic mechanisms in short telomere syndrome and their association with myelodysplastic syndromes and acute myeloid leukemia (MDS/AML). Somatic reversion events in six telomere-related genes were found to be more prevalent in patients who were MDS/AML-free, and no patient with MDS/AML had more than one reversion mutation.

“Our data identify diverse adaptive somatic mechanisms in the short telomere syndrome; they raise the possibility that their presence alleviates the telomere crisis that promotes transformation to MDS/AML,” the researchers concluded.

Somatic Mechanism Evolution of MDS and AML in Short Telomere Disorders

Want to See More Oncology News?

Be sure to keep up with the latest oncology news and research here on DocWire, updated daily!

Hematology & Oncology